In a phase IIb study [52], researchers found that ZW was well tolerated and that patients with HER2-positive biliary tract cancer benefited more than those with low HER2 expression, as reflected in a longer median PFS (5.5 vs. 1.9 months). This evidence concerns the gene ERBB2 and biliary tract cancer.